Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 10,951

Document Document Title
WO/2011/071947A3
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invent...  
WO/2011/067266A1
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2011/067174A1
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2011/065502A1
Disclosed are: a method for producing a fluorosulfonyl imide salt, which is capable of reducing the impurity content and can be continuously performed for a long time; and a fluorosulfonyl imide salt. The fluorosulfonyl imide salt has a ...  
WO/2011/061590A1
The present invention relates to carboxamide derivatives of Formula (I), where B1, B2, X, L, n, R, R1, R2, Z1, Z2, Rx and Ry are as defined in the claims, as compounds and compositions for inhibiting Human Immunodeficiency Virus (HIV) an...  
WO/2011/058154A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2011/055142A2
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...  
WO/2011/055142A3
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...  
WO/2011/052601A1
Provided are a novel ionic organic compound represented by general formula (I), which is effective as a carbon nanotube dispersant, and a method for producing said compound by means of simple processes. (In the formula, R1, R2, and R3 re...  
WO/2011/048004A1
This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevent...  
WO/2011/047795A1
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...  
WO/2011/047788A1
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...  
WO/2011/048152A1
The present invention relates to novel lithium salts which comprise pentafluorophenylamide anions and are of the general formula Li+[N(SO2-R)(C6F5)]-, which are optionally present as solvent-free complexes. R is selected from fluorine, l...  
WO/2011/046793A1
A compound of Formula (I), wherein Ra is linear or branched F(CF2)n(CH2CF2)m-, or linear or branched F(CF2)o interrupted by 1 to 6 catenary oxygen atoms, each oxygen bonded to two carbon atoms, m is 1 to 4, n is 2 to 6, o is 2 to 7, A is...  
WO/2011/046795A1
|A method of providing a surface effect to a medium or substrate comprising contacting the medium or substrate with a compound of formula (I) : wherein Ra is linear or branched F(CF2)n(CH2CF2)m-, or linear or branched F(CF2)r-O-B-; B is ...  
WO/2011/046954A1
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...  
WO/2011/043456A1
Disclosed is a compound represented by formula (I) or the like, which has a PAI-1 inhibitory effect. (In the formula, R1 represents an optionally substituted C6-10 aryl group or the like; R2 represents an optionally substituted C6-10 ary...  
WO/2011/043519A3
The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C rec...  
WO/2011/043519A2
The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C rec...  
WO/2011/033518A1
The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R1 is selected from optionally substituted C4-C9 alkyl, optionally substituted C6-C10 aryl, optionally substituted C6-C10...  
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2011/029842A1
The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of t...  
WO/2011/027867A1
Provided is a method for producing bis(sulfonyl)imide ammonium salts, bis(sulfonyl)imide, and bis(sulfonyl)imide lithium salts in a simple manner and with good yield. A method for producing bis(sulfonyl)imide ammonium salts, wherein ammo...  
WO/2011/026778A3
The invention relates to a method and a device for producing alkylamines and alkylamine derivatives from alkanes. According to the invention, at least one boric acid is reacted with at least one alkane with the addition of energy in the ...  
WO/2011/026682A1
The invention relates to immobilized rhodium (III), ruthenium (II), or iridium (III) catalysts for asymmetric hydrogenation reactions.  
WO/2011/025982A3
The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...  
WO/2011/016050A3
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvat...  
WO/2011/016050A2
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvat...  
WO/2011/009541A1
The present invention relates to the preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxy phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxy p...  
WO/2011/006908A3
Compounds comprising a metal complex having the structure [X-Y-Z-Mn+]p+. B are disclosed in which X is a histone deacetylase inhibitor, Mn+ is a DNA -binding heavy metal ion, Y is an aliphatic or aromatic spacer or is absent, and Z is a ...  
WO/2011/005396A1
A fluorinated bis(acyl)-containing compound of Formula (I), where R1, Ar, L, R2, R3, Rf, n, p and q are as defined in the claims, and a fluorinated polyester formed from the fluorinated bis(acyl) compound are described. More particularly...  
WO/2011/005642A1
Current methods for making polyfluorosulfonamido amines, which involve the use of a diamine reactant, provide low yields and produce an undesirable fluorine containing bis-sulfonamide by-product representing an economic loss. The bis-sul...  
WO/2011/000994A1
New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted n-phenetyl sulphonamides which can be biologically and pharmacologically traced, in order to be used in the ...  
WO/2011/002814A2
Some embodiments of the present invention include novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. Some compounds provided include tho...  
WO/2011/000863A1
The invention relates to novel sulfonamide derivatives, their preparation as well as to their use as BK 1 antagonists. Furthermore, the invention relates to topical compositions comprising such novel sulfonamide derivatives and their use...  
WO/2011/002814A3
Some embodiments of the present invention include novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. Some compounds provided include tho...  
WO/2011/000566A3
The present invention relates to novel compounds and pharmaceutical compositions and the use thereof for the manufacture of a medicament for treating, ameliorating, or preventing disease conditions caused by a viral infection with negati...  
WO/2010/150192A1
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I) as defined in the specification. The invention is also directed to compositions cont...  
WO/2010/149821A1
New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted N-phenethyl sulfonamide libraries which can be used in the search for, and identification of, new lead compo...  
WO/2010/151639A2
An organic electrolyte solvent includes a compound of the formula: R1-SO2-NR2-OR3 wherein R1 is selected from alkanes, alkenes, alkynes, aryls and their substituted derivatives and perfiuorinated analogues; R2 is selected from alkanes, a...  
WO/2010/151639A3
An organic electrolyte solvent includes a compound of the formula: R1-SO2-NR2-OR3 wherein R1 is selected from alkanes, alkenes, alkynes, aryls and their substituted derivatives and perfiuorinated analogues; R2 is selected from alkanes, a...  
WO/2010/144959A1
The present invention relates to analogues of anti-fibrotic agents having the formula (I) with the substituents as described within the specification. The present invention also relates to methods for their preparation.  
WO/2010/147666A1
Compounds are disclosed that have formula (I'): wherein A, W, Cy1, Cy2, L1, L2, R1 and R2 are as defined herein. The compounds and pharmaceutical compositions thereof are useful as probes and imaging agents for identifying hypoxic tumors...  
WO/2010/147228A1
A pattern forming method, including: (i) forming a film from a chemical amplification resist composition; (ii) exposing the film, so as to form an exposed film; and (iii) developing the exposed film by using a developer containing an org...  
WO/2010/146236A1
The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially α2β1 integrin inhibitors e.g. in connecti...  
WO/2010/139481A1
The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonis...  
WO/2010/137620A1
Disclosed is a phenoxyethylamine derivative having an excellent selective α1D adrenergic receptor antagonistic activity. Specifically disclosed is a compound represented by formula (I) [wherein each symbol is as defined in the descripti...  
WO/2010/133748A1
A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors a...  
WO/2010/132016A1
The invention provides compounds of formula (I) wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes ...  
WO/2010/132670A3
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...  

Matches 401 - 450 out of 10,951